Beijing Cancer Hospital - Beijing Institute for Cancer Research

Beijing 100142

0 studies enrolling now · 1 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung

Studies at this site

• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer — Stopped early